SAREPTA THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
SAREPTA THERAPEUTICS, INC. (SRPT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 27.84 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 27.84M shares, a 235.15% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 8.02M shares, a 60.80% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 8.31M shares.
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 20.45M shares, a 65.34% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 28.66M shares, a 1037.50% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.52M shares, a 88.28% decline from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 21.50M shares, a 14.15% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 25.04M shares, a 158.16% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 27.84M shares 10-Q · filed 2026-08-05 | 8.29M shares 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | 8.02M shares 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | 28.66M shares 10-K · filed 2026-03-02 | |||||||
| 2025-09-30 | 26.36M shares 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | 8.31M shares 10-Q · filed 2026-08-05 | 18.91M shares 10-Q · filed 2026-08-05 | 8.31M shares 10-Q · filed 2025-08-06 | |||||
| 2025-03-31 | 20.45M shares 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | 2.52M shares 10-K · filed 2026-03-02 | |||||||
| 2024-09-30 | 10.56M shares 10-Q · filed 2025-11-06 | |||||||
| 2024-06-30 | 10.98M shares 10-Q · filed 2025-08-06 | |||||||
| 2024-03-31 | 12.37M shares 10-Q · filed 2025-05-06 | |||||||
| 2023-12-31 | 21.50M shares 10-K · filed 2026-03-02 | 12.00M shares 10-K · filed 2024-02-28 | ||||||
| 2023-09-30 | 12.10M shares 10-Q · filed 2023-11-01 | 21.65M shares 10-Q · filed 2024-11-06 | 12.10M shares 10-Q · filed 2023-11-01 | |||||
| 2023-06-30 | 21.86M shares 10-Q · filed 2024-08-07 | 12.30M shares 10-Q · filed 2023-08-02 | ||||||
| 2023-03-31 | 22.09M shares 10-Q · filed 2024-05-01 | 12.60M shares 10-Q · filed 2023-05-02 | ||||||
| 2022-12-31 | 25.04M shares 10-K · filed 2025-02-28 | 11.20M shares 10-K · filed 2023-02-28 | ||||||
| 2022-09-30 | 11.20M shares 10-Q · filed 2023-11-01 | 11.20M shares 10-Q · filed 2023-11-01 | ||||||
| 2022-06-30 | 11.30M shares 10-Q · filed 2022-08-02 | 11.30M shares 10-Q · filed 2023-08-02 | ||||||
| 2022-03-31 | 11.30M shares 10-Q · filed 2023-05-02 | |||||||
| 2021-12-31 | 9.70M shares 10-K · filed 2024-02-28 | |||||||
| 2021-09-30 | 9.60M shares 10-Q · filed 2022-11-02 | 9.60M shares 10-Q · filed 2022-11-02 | ||||||
| 2021-06-30 | 9.80M shares 10-Q · filed 2022-08-02 | 9.80M shares 10-Q · filed 2022-08-02 | 10.00M shares 10-Q · filed 2021-08-04 | |||||
| 2021-03-31 | 10.30M shares 10-Q · filed 2022-05-04 | |||||||
| 2020-12-31 | 9.00M shares 10-K · filed 2023-02-28 | |||||||
| 2020-09-30 | 9.60M shares 10-Q · filed 2021-11-03 | 9.60M shares 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | 9.80M shares 10-Q · filed 2021-08-04 | 10.00M shares 10-Q · filed 2020-08-05 | 10.00M shares 10-Q · filed 2021-08-04 | |||||
| 2020-03-31 | 10.50M shares 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | 9.10M shares 10-K · filed 2022-03-01 | |||||||
| 2019-09-30 | 9.60M shares 10-Q · filed 2020-11-05 | 9.60M shares 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | 9.70M shares 10-Q · filed 2020-08-05 | 9.70M shares 10-Q · filed 2020-08-05 | ||||||
| 2019-03-31 | 9.80M shares 10-Q · filed 2020-05-06 | |||||||
| 2018-12-31 | 9.10M shares 10-K · filed 2021-03-01 | |||||||
| 2018-09-30 | 9.20M shares 10-Q · filed 2019-11-07 | 9.20M shares 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | 9.40M shares 10-Q · filed 2019-08-07 | 9.40M shares 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | 9.90M shares 10-Q · filed 2019-05-08 | |||||||
| 2017-12-31 | 9.40M shares 10-K · filed 2020-02-26 | |||||||
| 2017-09-30 | 9.80M shares 10-Q · filed 2018-10-31 | 9.80M shares 10-Q · filed 2018-10-31 | ||||||
| 2017-06-30 | 10.10M shares 10-Q · filed 2018-08-08 | 7.00M shares 10-Q · filed 2018-08-08 | ||||||
| 2017-03-31 | 3.40M shares 10-Q · filed 2018-05-03 | |||||||
| 2016-12-31 | 5.70M shares 10-K · filed 2019-02-28 | |||||||
| 2016-09-30 | 6.30M shares 10-Q · filed 2017-11-01 | 6.30M shares 10-Q · filed 2017-11-01 | ||||||
| 2016-06-30 | 7.30M shares 10-Q · filed 2017-08-03 | 7.30M shares 10-Q · filed 2017-08-03 | ||||||
| 2016-03-31 | 7.90M shares 10-Q · filed 2017-05-04 | |||||||
| 2015-12-31 | 6.80M shares 10-K · filed 2018-03-01 | |||||||
| 2015-09-30 | 7.30M shares 10-Q · filed 2016-11-07 | 7.30M shares 10-Q · filed 2016-11-07 | ||||||
| 2015-06-30 | 7.00M shares 10-Q · filed 2016-08-09 | 7.00M shares 10-Q · filed 2016-08-09 | ||||||
| 2015-03-31 | 6.90M shares 10-Q · filed 2016-05-05 | 6.94M shares 10-Q · filed 2015-05-07 | ||||||
| 2014-12-31 | 5.40M shares 10-K · filed 2017-02-28 | 5.39M shares 10-K · filed 2015-02-26 | ||||||
| 2014-09-30 | 5.30M shares 10-Q · filed 2015-11-05 | 5.31M shares 10-Q · filed 2014-11-06 | 5.30M shares 10-Q · filed 2015-11-05 | 5.31M shares 10-Q · filed 2014-11-06 | ||||
| 2014-06-30 | 5.90M shares 10-Q · filed 2015-08-06 | 5.91M shares 10-Q · filed 2014-08-07 | 5.90M shares 10-Q · filed 2015-08-06 | 5.91M shares 10-Q · filed 2014-08-07 | ||||
| 2014-03-31 | 6.10M shares 10-Q · filed 2015-05-07 | |||||||
| 2013-12-31 | 5.20M shares 10-K · filed 2016-02-25 | 5.16M shares 10-K · filed 2014-03-03 | ||||||
| 2013-09-30 | 5.29M shares 10-Q · filed 2014-11-06 | 5.29M shares 10-Q · filed 2014-11-06 | ||||||
| 2013-06-30 | 6.79M shares 10-Q · filed 2014-08-07 | 6.79M shares 10-Q · filed 2014-08-07 | ||||||
| 2013-03-31 | 6.00M shares 10-Q · filed 2014-05-08 | |||||||
| 2012-12-31 | 5.86M shares 10-K · filed 2015-02-26 | |||||||
| 2012-09-30 | 7.37M shares 10-Q · filed 2013-11-12 | 7.37M shares 10-Q · filed 2013-11-12 | ||||||
| 2012-06-30 | 6.95M shares 10-Q · filed 2013-08-08 | 6.99M shares 10-Q · filed 2013-08-08 | ||||||
| 2011-12-31 | 7.29M shares 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |